港股异动 | 百奥赛图涨超10%，科创版IPO即将接受审议，月初与默克达成抗体授权合作

智通财经2025-09-18

9月18日（周四），百奥赛图-B涨超10%，截至发稿，涨10.12%，报27.42港元，成交额1316万港元。消息面上，9月17日，上交所上市审核委员会发布公告，百奥赛图的科创板IPO迎来关键节点，首发事项将于9月24日接受审议。此次科创板IPO，百奥赛图计划募集资金11.85亿元，募集资金将投向药物早期研发服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目、补充流动资金。值得注意的是...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2568444695?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","is_english":false,"pubTime":"2025-09-18 10:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568444695","market":"hk","top_or_hot":-1,"title":"港股异动 | 百奥赛图涨超10%，科创版IPO即将接受审议，月初与默克达成抗体授权合作","media":"智通财经","content":"<div>\n<p>9月18日（周四），百奥赛图-B涨超10%，截至发稿，涨10.12%，报27.42港元，成交额1316万港元。消息面上，9月17日，上交所上市审核委员会发布公告，百奥赛图的科创板IPO迎来关键节点，首发事项将于9月24日接受审议。此次科创板IPO，百奥赛图计划募集资金11.85亿元，募集资金将投向药物早期研发服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目、补充流动资金。值得注意的是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1346617.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 百奥赛图涨超10%，科创版IPO即将接受审议，月初与默克达成抗体授权合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 百奥赛图涨超10%，科创版IPO即将接受审议，月初与默克达成抗体授权合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-18 10:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1346617.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>9月18日（周四），百奥赛图-B涨超10%，截至发稿，涨10.12%，报27.42港元，成交额1316万港元。消息面上，9月17日，上交所上市审核委员会发布公告，百奥赛图的科创板IPO迎来关键节点，首发事项将于9月24日接受审议。此次科创板IPO，百奥赛图计划募集资金11.85亿元，募集资金将投向药物早期研发服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目、补充流动资金。值得注意的是...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1346617.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1035773651.USD","symbol_name":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1346617.html","article_id":"2568444695","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568444695","pubTimestamp":1758160893,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"9月18日（周四），$百奥赛图-B$涨超10%，截至发稿，涨10.12%，报27.42港元，成交额1316万港元。消息面上，9月17日，上交所上市审核委员会发布公告，百奥赛图的科创板IPO迎来关键节点，首发事项将于9月24日接受审议。根据协议条款，百奥赛图将提供基于其RenMice平台自主开发的全人抗体，由默克评估将其用于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权，百奥赛图有权获得相应的费用付款及销售分成和再许可分成。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159982":"中证500","LU1035773651.USD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (USD) INC","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","BK1161":"生物科技","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1069347547.HKD":"AB SICAV I - GLOBAL VALUE PORTFOLIO \"AD\" (HKD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","MRK":"默沙东","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","YANG":"三倍做空富时中国ETF-Direxion","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0238689110.USD":"贝莱德环球动力股票基金","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1116320737.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999014542.SGD":"United Income Focus Trust Acc SGD","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","HSCEI":"国企指数","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU0861579265.USD":"联博低波幅策略股票基金A","BK4559":"巴菲特持仓","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4614":"Manus概念股","02315":"百奥赛图-B"},"translate_title":"Changes in Hong Kong stocks | Biocyto-B (02315) rose more than 15% in early trading. The IPO of the science and technology innovation version is about to be held. The company reached an antibody licensing cooperation with Merck at the beginning of the month","themeId":"1c2e6bc5fe5e88020e64b175354f9941","isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/6d457fdbb43c932b6bb88a7659a48be4","symbols_score_info":{"159982":1.5,"02315":1.5,"YANG":1.5,"MRK":1.5,"HSCEI":1.5},"content_text":"9月18日（周四），百奥赛图-B涨超10%，截至发稿，涨10.12%，报27.42港元，成交额1316万港元。消息面上，9月17日，上交所上市审核委员会发布公告，百奥赛图的科创板IPO迎来关键节点，首发事项将于9月24日接受审议。此次科创板IPO，百奥赛图计划募集资金11.85亿元，募集资金将投向药物早期研发服务平台建设项目、抗体药物研发及评价项目、临床前及临床研发项目、补充流动资金。值得注意的是，本月初，据百奥赛图官微消息，公司与全球领先的科技公司默克(Merck)已签署一项抗体选择权的评估协议，推进开发应用于核酸药物的抗体偶联脂质递送解决方案，例如抗体偶联脂质纳米颗粒(LNP)。根据协议条款，百奥赛图将提供基于其RenMice®平台自主开发的全人抗体，由默克评估将其用于抗体偶联LNP制剂服务的可行性。默克被授予获取选中抗体资产权益的独家选择权，百奥赛图有权获得相应的费用付款及销售分成和再许可分成。","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2568444695","isCrawlerRequest":true}